1. Home
  2. PRME vs ACNB Comparison

PRME vs ACNB Comparison

Compare PRME & ACNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.07

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Logo ACNB Corporation

ACNB

ACNB Corporation

HOLD

Current Price

$60.70

Market Cap

595.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
ACNB
Founded
2019
1857
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
536.4M
595.5M
IPO Year
2022
1994

Fundamental Metrics

Financial Performance
Metric
PRME
ACNB
Price
$3.07
$60.70
Analyst Decision
Buy
Buy
Analyst Count
6
1
Target Price
$7.56
$58.00
AVG Volume (30 Days)
4.4M
71.9K
Earning Date
05-08-2026
04-23-2026
Dividend Yield
N/A
3.00%
EPS Growth
18.18
N/A
EPS
N/A
1.32
Revenue
$4,632,000.00
$191,821,000.00
Revenue This Year
$7.06
$13.18
Revenue Next Year
$47.01
$1.91
P/E Ratio
N/A
$46.09
Revenue Growth
55.28
45.10
52 Week Low
$2.67
$41.03
52 Week High
$6.94
$62.07

Technical Indicators

Market Signals
Indicator
PRME
ACNB
Relative Strength Index (RSI) 41.07 60.68
Support Level $2.68 $48.10
Resistance Level $3.82 $61.73
Average True Range (ATR) 0.32 1.38
MACD -0.11 -0.04
Stochastic Oscillator 0.57 71.13

Price Performance

Historical Comparison
PRME
ACNB

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About ACNB ACNB Corporation

ACNB Corp is the financial holding company. Through its wholly-owned subsidiaries, it provides a full range of retail and commercial financial services in Pennsylvania and Maryland through its network of community banking offices. It also provides property, casualty, health, life and disability insurance serving personal and commercial clients through offices in Westminster, Maryland, and Gettysburg, Pennsylvania and is licensed to do business. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage; and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.

Share on Social Networks: